Clinical trials and observational studies provide evidence for a wide range of interventions of proven value for preventing a first or recurrent stroke. The available data indicate that strategies for primordial, primary and secondary stroke prevention are not being optimally implemented. Although specific estimates are difficult to calculate, the impact of improving the use of the wide array of effective stroke preventive interventions would be substantial.
EUSI Executive Committee and EUSI Writing Committee: European Stroke Initiative: Ischaemic Stroke - Prophylaxis and Treatment. Heidelberg, Germany: EUSI Executive Committee and EUSI Writing Committee, 2003.
2.
GoldsteinLBAdamsRAlbertsMJPrimary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke2006; 37:1583–633.
3.
NorrisJWPerryJRDjanP: Stroke prevention by screening for asymptomatic carotid stenosis: validation of evidence-based guidelines. Neurology1996; 46(Suppl): A325.
4.
HaydenMPigoneMPhillipsCMulrowC: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US preventive services task force. Ann Intern Med2002; 136:161–72.
5.
AlbersGWAmarencoPEastonJDSaccoRLTealP: Antithrombotic and thrombolytic therapy for ischemic stroke. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest2004; 126(Suppl): 483S–512S.
6.
SaccoRLAdamsRAlbersGGuidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke2006; 37:577–617.
AdamsHPJrdel ZoppoGAlbertsMJGuidelines for the early management of adults with ischemic stroke. Stroke2007; 38:1655–711.
9.
PearsonTABazzarreTDanielsSRAHA guide for improving cardiovascular health at the community level. A statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association expert panel on population and prevention science. Circulation2003; 107:645–51.
10.
American Heart Association: Heart disease and stroke statistics - 2008 update. Dallas, Texas, American Heart Association, 2008:15.
11.
WhisnantJP: Modeling of risk factors for ischemic stroke. The Willis Lecture. Stroke1997; 28:1840–4.
12.
SamsaGPCohenSJGoldsteinLBKnowledge of risk among patients at increased risk for stroke. Stroke1997; 28:916–21.
13.
KothariRSauerbeckLJauchEPatients' awareness of stroke signs, symptoms, and risk factors. Stroke1997; 28:1871–5.
14.
PancioliAMBroderickJKothariRPublic perception of stroke warning signs and knowledge of potential risk factors. JAMA1998; 279:1288–92.
15.
Sug YoonSHellerRFLeviCWiggersJFitzgeraldPE: Knowledge of stroke risk factors, warning symptoms, and treatment among an Australian urban population. Stroke2001; 32:1926–30.
16.
ParahooKThompsonKCooperMStringerMEnnisEMcCollamP: Stroke: awareness of the signs, symptoms and risk factors - a population-based survey. Cerebrovas Dis2003; 16:134–40.
17.
SchneiderATPancioliAMKhouryJCTrends in community knowledge of the warning signs and risk factors for stroke. JAMA2003; 289:343–6.
18.
SilverFLRubiniFBlackDHodgsonCS: Advertising strategies to increase public knowledge of the warning signs of stroke. Stroke2003; 34:1965–9.
19.
RulandSRamanRChaturvediSLeurgansSGorelickPB: Awareness, treatment, and control of vascular risk factors in African Americans with stroke. Neurology2003; 60:64–8.
20.
NedeltchevKFischerUArnoldMKappelerLMattleHP: Low awareness of transient ischemic attacks and risk factors of stroke in a Swiss urban community. J Neurol2007; 254:179–84.
21.
DeLemosCDAtkinsonRPCroopnickSLWentworthDAAkinsPT: How effective are ‘community’ stroke screening programs at improving stroke knowledge and prevention practices? Results of a 3-month follow-up study. Stroke2003; 34:E247–9.
22.
SaccoRL: The 2006 William Feinberg lecture: shifting the paradigm from stroke to global vascular risk estimation. Stroke2007; 38:1980–7.
23.
HowardGSaffordMMMeschiaJFStroke symptoms in individuals reporting no prior stroke or transient ischemic attack are associated with a decrease in indices of mental and physical functioning. Stroke2007; 38:2446–52.
24.
WadleyVGMcClureLAHowardVJCognitive status, stroke symptom reports, and modifiable risk factors among individuals with no diagnosis of stroke or transient ischemic attack in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Stroke2007; 38:1143–7.
25.
VernooijMWIkramMATangheHLIncidental findings on brain MRI in the general population. N Engl J Med2007; 357: 1821–8.
26.
HollowayRGBeneschCRushSR: Stroke prevention. Narrowing the evidence-practice gap. Neurology2000; 54:1899–906.
27.
TsangTSPettyGWBarnesMEThe prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol2003; 42:93–100.
28.
MariniCDe SantisFSaccoSContribution of atrial fibrillation to incidence and outcome of ischemic stroke - results from a population-based study. Stroke2005; 36:1115–9.
29.
HartRGPearceLAAguilarMI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med2007; 146:857–67.
30.
PettyGWBrownRDJWhisnantJPSicksJDO'FallonWMWiebersDO: Survival and recurrence after first cerebral infarction - a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology1998; 50:208–16.
31.
VickreyBGRectorTSWickstromSLOccurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke2002; 33:901–6.
32.
HankeyGJJamrozikKBroadhurstRJFive-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke2000; 31:2080–6.
33.
DhamoonMSTaiWBoden-AlbalaBRisk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke2007; 38:1752–8.
34.
PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet2001; 358:1033–41.
35.
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med2006; 355:549–59.
36.
AlgraAvan GijnJ: Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol, Neurosurg Psychiatry1996; 60:197–9.
37.
HankeyGJWarlowCP: Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet1999; 354:1457–63.
38.
ESPRIT Study Group: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet2006; 367:1665–73.
39.
RothwellPMEliasziwMGutnikovSAAnalysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet2003; 361:107–16.
40.
JencksSFHuffEDCuerdonT: Change in the quality of care delivered to Medicare beneficiaries, 1998–1999 to 2000–2001. JAMA2003; 289:305–12.
41.
Scholte op ReimerWJDippelDWFrankeCLQuality of hospital and outpatient care after stroke or transient ischemic attack: insights from a stroke survey in the Netherlands. Stroke2006; 37:1844–9.
42.
JohnsonPRosewellMJamesMA: How good is the management of vascular risk after stroke, transient ischaemic attack or carotid endarterectomy?Cerebrovasc Dis2007; 23:156–61.
43.
BraininMTeuschlYKalraL: Acute treatment and long-term management of stroke in developing countries. Lancet Neurol2007; 6:553–61.
44.
HackamDGSpenceJD: Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke2007; 38:1881–5.
45.
GoldsteinLB: Gaps in professional and community knowledge about stroke prevention and treatment; in GorelickPBAlterM (eds): Stroke Prevention. Boca Raton: Parthenon Publishing, 2002: 149–54.
46.
GemsonDHElinsonJ: Prevention in primary care: variability in physician practice patterns in New York City. Am J Prev Med1986; 2:226–34.
47.
GoldsteinLBBonitoAJMatcharDBDuncanPWSamsaGP: U.S. national survey of physician practices for the secondary and tertiary prevention of ischemic stroke: carotid endarterectomy. Stroke1996; 27:801–6.
48.
GoldsteinLBBonitoAJMatcharDBU.S. national survey of physician practices for the secondary and tertiary prevention of stroke: design, service availability, and common practices. Stroke1995; 26:1607–15.
49.
LomasJ: Words without action? The production, dissemination, and impact of consensus recommendations. Annu Rev Publ Health1991; 12:41–65.
50.
GrecoPJEisenbergJM: Changing physician's practices. N Engl J Med1993; 329: 1271–4.
51.
DeplanqueDLeysDParnettiLStroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol2004; 57:798–806.
